BGLA.F Stock Overview
A healthcare company, provides probiotic products worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 4/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
BioGaia AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 10.50 |
| 52 Week High | SEK 12.70 |
| 52 Week Low | SEK 9.96 |
| Beta | 0.59 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | 2.64% |
| 33 Year Change | -5.91% |
| 5 Year Change | 30.11% |
| Change since IPO | 1,093.18% |
Recent News & Updates
Recent updates
Shareholder Returns
| BGLA.F | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | 4.0% | 2.2% |
| 1Y | 2.6% | 18.3% | 32.6% |
Return vs Industry: BGLA.F underperformed the US Biotechs industry which returned 16.1% over the past year.
Return vs Market: BGLA.F underperformed the US Market which returned 31.6% over the past year.
Price Volatility
| BGLA.F volatility | |
|---|---|
| BGLA.F Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: BGLA.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine BGLA.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1990 | 222 | Theresa Agnew | www.biogaia.com |
BioGaia AB (publ), a healthcare company, provides probiotic products worldwide. The company operates through Pediatrics, Adult Health, and Other segments. The Pediatrics segment offers drops, oral rehydration solutions, and gut health tablets, as well as cultures that are used as an ingredient in infant formula.
BioGaia AB (publ) Fundamentals Summary
| BGLA.F fundamental statistics | |
|---|---|
| Market cap | US$969.87m |
| Earnings (TTM) | US$30.64m |
| Revenue (TTM) | US$123.31m |
31.7x
P/E Ratio7.9x
P/S RatioIs BGLA.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BGLA.F income statement (TTM) | |
|---|---|
| Revenue | SEK 1.36b |
| Cost of Revenue | SEK 358.07m |
| Gross Profit | SEK 997.60m |
| Other Expenses | SEK 660.78m |
| Earnings | SEK 336.82m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 12, 2025
| Earnings per share (EPS) | 3.33 |
| Gross Margin | 73.59% |
| Net Profit Margin | 24.85% |
| Debt/Equity Ratio | 0% |
How did BGLA.F perform over the long term?
See historical performance and comparison